CAMERA Newsletters

The CAMERA Study continues to advance our understanding of dementia risk across diverse populations in Canada. This issue highlights our first publication, updates to the study schedule, and exciting new imaging capabilities with Sunnybrook’s 7T MRI scanner. We also explore emerging research on early brain changes, including the role of the blood–brain barrier and innovative, less invasive diagnostic approaches.

Health Canada has approved Leqembi (lecanemab), the first Alzheimer’s treatment in Canada aimed at the disease’s biology for people with early symptoms—we outline access and safety considerations. We also explain how loneliness raises dementia risk and ways to stay connected, recap our team’s week at AAIC in Toronto, celebrate Dr. Jenny Rabin’s promotion to Associate Professor, and share progress toward our 300-participant goal.

In this issue, we explore how sleep impacts brain health and dementia risk, share updates on new Alzheimer’s medications under review in Canada, and highlight CAMERA findings showing the need for more inclusive dementia screening tools. We also celebrate Madeline Wood Alexander’s Research Excellence Award and invite you to AAIC For All, a free community event in Toronto this July. With your support, we continue advancing equity in brain health research.